Item Type | Name |
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
Concept
|
Chemotherapy, Adjuvant
|
Concept
|
Induction Chemotherapy
|
Academic Article
|
Treatment of metastatic urothelial cancer in the post-MVAC era.
|
Academic Article
|
Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study.
|
Academic Article
|
Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.
|
Academic Article
|
Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma.
|
Academic Article
|
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
|
Academic Article
|
Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment.
|
Academic Article
|
The expanding role of systemic therapy in head and neck cancer.
|
Academic Article
|
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
|
Academic Article
|
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
|
Academic Article
|
Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer.
|
Academic Article
|
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
|
Academic Article
|
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
|
Academic Article
|
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.
|
Academic Article
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
Academic Article
|
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
|
Academic Article
|
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
|
Academic Article
|
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.
|
Academic Article
|
Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy.
|
Academic Article
|
Planned post-chemoradiation neck dissection: significance of radiation dose.
|
Academic Article
|
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.
|
Academic Article
|
Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy.
|
Academic Article
|
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
|
Academic Article
|
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
|
Academic Article
|
Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer.
|
Academic Article
|
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
|
Academic Article
|
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
|
Academic Article
|
Searching for a standard.
|
Academic Article
|
Locally advanced non-small cell lung cancer.
|
Academic Article
|
Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer.
|
Academic Article
|
Esophageal cancer therapy: a decade of inertia.
|
Academic Article
|
Current treatment options for metastatic head and neck cancer.
|
Academic Article
|
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
|
Academic Article
|
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
|
Academic Article
|
Pharmacoeconomic issues in head and neck oncology.
|
Academic Article
|
Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors.
|
Academic Article
|
New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors.
|
Academic Article
|
The role of chemotherapy in locally advanced head and neck squamous cell carcinoma.
|
Academic Article
|
The future of induction chemotherapy for head and neck squamous cell carcinoma.
|
Academic Article
|
DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer.
|
Academic Article
|
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
|
Academic Article
|
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
|
Academic Article
|
Reply to s. Chakraborty et al.
|
Academic Article
|
Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
|
Academic Article
|
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
|
Academic Article
|
A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
|
Academic Article
|
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
|
Academic Article
|
Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.
|
Academic Article
|
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.
|
Academic Article
|
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
|
Academic Article
|
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
|
Academic Article
|
Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC).
|
Academic Article
|
Phase II trial pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated head and neck cancer patients.
|
Academic Article
|
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
|
Academic Article
|
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions.
|
Academic Article
|
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
|
Academic Article
|
A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers.
|
Academic Article
|
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.
|
Academic Article
|
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
|
Academic Article
|
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.
|
Academic Article
|
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors.
|
Academic Article
|
HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
|
Academic Article
|
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.
|
Academic Article
|
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
|
Academic Article
|
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.
|
Academic Article
|
Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
|
Academic Article
|
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
|
Academic Article
|
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
|
Academic Article
|
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.
|
Academic Article
|
Role of Induction Chemotherapy Prior to Chemoradiation in Head and Neck Squamous Cell Cancer-Systematic Review and Meta-analysis.
|
Academic Article
|
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
|
Academic Article
|
A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
|
Grant
|
Functional Infrared Imaging Predicts Radiation Mucositis
|
Academic Article
|
Eganelisib, a First-in-Class PI3K? Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
|